title: [Isoprinosine and climatotherapy at the Czerniawa-Zdrój health resort in the treatment of children with recurrent respiratory tract infections].
abstract: The authors used in children in with recurrent respiratory infections in 28 cases isoprenosine, in 30 climatic therapy and in 15 isoprenosine followed by climatic therapy. Isoprenosine was used in a dose 50 mg per kg b.w. for two weeks, followed by 10 days of an interruption, after which isoprenosine was gain given for ten days. Climatic therapy was carried out for six weeks. Thirty healthy children of the same age made up the control. Good or excellent results were seen in 19 out of 28 children treated with isoprenosine, in 16 out of 30 that underwent climatic therapy, and 11 out of 15 in which both modes were used. The authors discuss their own experience in treating children with recurrent respiratory infections suggesting that this model for treating sick cases be used, observing good results in two thirds.
authors: A
authors: A
authors: Jankowski
authors: W
authors: W
authors: Kowalik
authors: Z
authors: Z
authors: Szyszka
authors: W
authors: W
authors: Sznajder
authors: U
authors: U
authors: Stasiewicz
authors: L
authors: L
authors: Szenborn
mesh_terms: D000276:Adjuvants, Immunologic; D000293:Adolescent; D001424:Bacterial Infections / Q000276:immunology / Q000628:therapy*; D001991:Bronchitis / Q000276:immunology / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D002980:Climate; D003131:Combined Modality Therapy; D005260:Female; D006294:Health Resorts; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D007288:Inosine / Q000031:analogs & derivatives*; D007542:Inosine Pranobex / Q000627:therapeutic use*; D008297:Male; D011014:Pneumonia / Q000276:immunology / Q000628:therapy*; D011044:Poland; D012008:Recurrence; D014069:Tonsillitis / Q000276:immunology / Q000628:therapy*
chemical_list: D000276:Adjuvants, Immunologic; D007288:Inosine; D007542:Inosine Pranobex
vernacular_title: Isoprinosina oraz klimatoterapia w czerniawie zdroju w leczeniu dzieci z nawracajacymi zakazeniami dróg oddechowych.